

Trial targets deadly lung cancer

October 30 2020



Associate Professor Sonja Klebe, leader of Asbestos Associated Disease research at Flinders University. Credit: Flinders University

With more than 650 Australians diagnosed with malignant mesothelioma last year, Flinders University is leading new research to discover alternatives to chemotherapy and even prevent deaths by early detection

in future.

One novel approach, using natural therapeutic benefits of curcumin, a key component of the spice turmeric, will be put to the test in a clinical trial in 2021 as part of world-leading research at Flinders University.

While asbestos is now banned from being used for new buildings, many houses still contain asbestos, so exposure during renovations is common. Australia has one of the highest per-capita rates of asbestos-related disease in the world.

Flinders University researchers are studying the safety and feasibility of using a form of intrapleural liposomal curcumins to benefit [patient survival](#) and quality of life—with fewer toxic side-effects than chemotherapy.

"That's why it's important to explore [alternative therapies](#) and facilitate early diagnosis to reduce suffering and support early intervention measures," says Flinders University lead researcher Associate Professor Sonja Klebe.

As well, the researchers are looking for early diagnostic methods with a special lung fluid test. "In most cases, malignant mesothelioma is not diagnosed until it is in the late stages," she says. "We're hoping to find a way to test for the disease before it becomes invasive."



Associate Professor Sonja Klebe with Dr Ash Hocking, postdoctoral research associate in the Flinders University Prof Doug Henderson Asbestos Associated Disease Laboratory. Credit: Flinders University

Patients diagnosed with malignant mesothelioma, the cancer caused by asbestos exposure, experience poor survival of 6-12 months following diagnosis and a five-year survival of less than 5%. Therapeutic options are limited due to high resistance rates to chemotherapy and the advanced age of patients (median age 75).

Associate Professor Klebe's team will test the safety and feasibility of

intrapleural liposomal curcumin to benefit patient survival and quality of life. Future treatments are expected to have fewer toxic side-effects than chemotherapy.

In addition, the researchers are investigating methods to facilitate [early diagnosis](#), using novel techniques on the lung fluid that is drained in the early stages of diagnosis.

"In most cases, [malignant mesothelioma](#) is not diagnosed until it is in the late stages," she says. "We're hoping to find a way to test for the disease before it becomes invasive."

In time for Asbestos Awareness Month in November, the experts warn the high number of cases could persist for years with hundreds more cases of the deadly disease possible after latency of more than 30 years from work-related (builders, plumbers, gasfitters, mechanics and marine engineers) or other exposure. Firefighters may also be at risk after the devastating bushfires razed old buildings and sheds across Australia.

More information: Emily Pulford et al, Malignant mesothelioma in situ: diagnostic and clinical considerations, *Pathology* (2020). [DOI: 10.1016/j.pathol.2020.06.010](#)

Provided by Flinders University

Citation: Trial targets deadly lung cancer (2020, October 30) retrieved 4 February 2024 from <https://medicalxpress.com/news/2020-10-trial-deadly-lung-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.